Consistent with the underlying prevalent comorbidities of the COVID-19 group, a history of prescription drugs use associated with managing hypertension or cardiovascular disease (ACE inhibitor, calcium channel blocker, β-blocker, aldosterone antagonists, antiarrhythmic, antiplatelet, anticoagulant), cholesterol (statin), inflammation (glucocorticoid, β2-agonists) or background HPB condition (proton pump inhibitor) was higher in patients with COVID-19 (table 2). This evidence concerns the gene ACE and cardiovascular disorder.